Memorial Sloan Kettering Cancer Center (MSK) just published results in the New England Journal of Medicine for a basket study for an early Phase II study, led by MSK Physician-in-Chief and Chief Medical Officer José Baselga, that looked at the effect of vemurafenib (Zelboraf) in multiple nonmelanoma BRAFV600-mutated cancers in 122 patients from 23 centers around the world. What is unique about this design is it focused on mutation rather than histology. This makes it far more likely to pick up activity in a host of tumors with this mutation more quickly than a traditional trial schema, where each tumor and mutation would be tested individually.

Memorial Sloan Kettering Cancer Center (MSK) just published results in the New England Journal of Medicine for a basket study for an early Phase II study, led by MSK Physician-in-Chief and Chief Medical Officer José Baselga, that looked at the effect of vemurafenib (Zelboraf) in multiple nonmelanoma BRAFV600-mutated cancers in 122 patients from 23 centers around the world. What is unique about this design is it focused on mutation rather than histology. This makes it far more likely to pick up activity in a host of tumors with this mutation more quickly than a traditional trial schema, where each tumor and mutation would be tested individually.